Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx) together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial

Trial Profile

Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx) together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms VOICE

Most Recent Events

  • 20 Jan 2018 Status changed from recruiting to completed, according to the results presented at the 2018 Gastrointestinal Cancers Symposium
  • 20 Jan 2018 Primary endpoint (Progression free survival) has been met. according to the results presented at the 2018 Gastrointestinal Cancers Symposium
  • 20 Jan 2018 Final results presented at the 2018 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top